- Home
- STHO vs ABOS Comparison
STHO vs ABOS Comparison
Compare STHO & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STHO
- ABOS
- Stock Information
- Founded
- STHO N/A
- ABOS 1996
- Country
- STHO United States
- ABOS United States
- Employees
- STHO N/A
- ABOS N/A
- Industry
- STHO Real Estate
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- STHO Real Estate
- ABOS Health Care
- Exchange
- STHO Nasdaq
- ABOS Nasdaq
- Market Cap
- STHO 153.3M
- ABOS 138.8M
- IPO Year
- STHO N/A
- ABOS 2021
- Fundamental
- Price
- STHO $9.63
- ABOS $1.85
- Analyst Decision
- STHO
- ABOS Strong Buy
- Analyst Count
- STHO 0
- ABOS 4
- Target Price
- STHO N/A
- ABOS $9.00
- AVG Volume (30 Days)
- STHO 77.6K
- ABOS 335.9K
- Earning Date
- STHO 11-05-2024
- ABOS 11-12-2024
- Dividend Yield
- STHO N/A
- ABOS N/A
- EPS Growth
- STHO N/A
- ABOS N/A
- EPS
- STHO 6.15
- ABOS N/A
- Revenue
- STHO $117,752,000.00
- ABOS N/A
- Revenue This Year
- STHO N/A
- ABOS N/A
- Revenue Next Year
- STHO N/A
- ABOS N/A
- P/E Ratio
- STHO $1.51
- ABOS N/A
- Revenue Growth
- STHO 13.35
- ABOS N/A
- 52 Week Low
- STHO $9.23
- ABOS $1.72
- 52 Week High
- STHO $15.31
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- STHO 18.97
- ABOS 32.26
- Support Level
- STHO $10.06
- ABOS $1.72
- Resistance Level
- STHO $10.47
- ABOS $2.03
- Average True Range (ATR)
- STHO 0.32
- ABOS 0.14
- MACD
- STHO -0.08
- ABOS -0.02
- Stochastic Oscillator
- STHO 5.77
- ABOS 19.42
About STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. It focuses on realizing value for shareholders from the legacy portfolio by maximizing cash flows through active asset management and asset sales.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.